This week, an additional 29 companies have announced! TIGERMED and several other stocks disclosed repurchase and shareholding refinancing plans, with a list of related A-shares overview.
① The number of A-share listed companies receiving special loan support continues to expand. According to incomplete Statistics, as of the time of writing, 29 listed companies have disclosed information related to share repurchase and increased shareholding for re-loan this week (see attached table); ② TIGERMED received the highest amount of special loan support, totaling no more than 0.7 billion yuan.
Qingdao Haier Biomedical Co., Ltd.'s merger plan for "Blood King" has failed.
A specific plan recognized by all relevant parties could not be formed.
Due to a lack of consensus among all parties, Qingdao Haier Biomedical Co., Ltd. has pressed the termination button on the merger with Shanghai RAAS Blood Products | Read the announcement quickly.
① The reason for terminating the reorganization is that the main shareholders of the trading parties and the merging parties failed to formulate a specific plan recognized by all relevant parties; ② Shanghai RAAS Blood Products and Qingdao Haier Biomedical Co., Ltd. will resume trading on January 7 and announce a share buyback simultaneously; ③ According to informed sources, the goal of Haier Group to expand its health sector will not change.
WUXI BIO has once again divested overseas Assets! Merck takes over WUXI BIO's Ireland vaccine factory for 0.5 billion USD | Quick read announcement.
① WUXI BIO announced today that it will sell the Ireland vaccine factory to Merck for 0.5 billion USD; ② this vaccine factory was originally built to undertake Merck's vaccine contract manufacturing business; ③ not long ago, WUXI APPTEC also divested its WuXi ATU business in the USA and United Kingdom.
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
The positive rate of influenza viruses nationwide continues to rise, and the sales of Against Influenza drugs continue to grow.
① According to the latest data from the China Center for Disease Control and Prevention, the positivity rate of influenza viruses continues to rise, with over 99% being type A influenza. ② As the number of influenza infections increases, the sales of antiviral drugs against influenza have also been growing recently. Currently, the antiviral flu medications available domestically mainly include Oseltamivir, Abidol, Mabalaosavir, Zanamivir, and Peramivir.